Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

PHASE4CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

December 4, 2017

Conditions
HIV
Interventions
DRUG

Dolutegravir

Dolutegravir 50mg once daily

Trial Locations (33)

100

CHU Saint-Pierre, Brussels

9000

Universitaire Ziekenhuis Gent, Ghent

20142

San Paolo Hospital, Milan

20146

ICH Infektiologisches Centrum Hamburg, Hamburg

20157

Azienda Ospedaliera - Polo Universitario 'Luigi Sacco', Milan

28034

Hospital Ramon y Cajal, Madrid

28046

Hospital Universitario La Paz, Madrid

30625

Medizinische Hochschule Hannover, Hanover

41124

Universitaria di Modena, Modena

44093

Service des Maladies Infectieuses et Tropicales du CHU de NANTES, Nantes

45147

Universitätsklinikum Essen, Essen

50011

Santa Maria Annunziata di Firenze, Florence

53127

Universitätsklinikum Bonn, Bonn

60590

Klinikum der Goethe-Universität Frankfurt, Frankfurt

69004

Hopital de la Croix Rousse, Lyon

75010

Hopital Saint Louis, Paris

75013

Pitié-Salpêtrière Hospital, Paris

75018

Hospital Bichat Claude-Bernard, Paris

B-2000

Insititute Of Tropical Medicine Antwerp, Antwerp

03010

Universitario Alicante, Alicante

03203

Hospital General Universitario de Elche, Alicante

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08036

Hospital Clinic Barcelona, Barcelona

08907

Universitari de Bellvitge, Barcelona

08916

IrsiCaixa, Barcelona

BN2 1ES

Elton John Centre, Brighton

BS10 5NB

Southmead Hospital, Bristol

E1 1BB

Bart's Hospital, London

NW3 2QG

Royal Free Hospital, London

SE1 7EH

St Thomas Hospital, London

Sw10 9NH

Chelsea & Westminster Hospital, London

W2 1NY

St Mary's Hospital, London

WC1E 6JB

Mortimer Market Centre, London

All Listed Sponsors
lead

St Stephens Aids Trust

OTHER

NCT02098837 - Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) | Biotech Hunter | Biotech Hunter